先天性心脏病复合畸形的介入治疗

目的探讨介入治疗小儿先天性心脏病(CHD)复合畸形的可行性和疗效。方法对CHD复合畸形患儿10例施行联合介入治疗,其中房间隔缺损(ASD)并肺动脉瓣狭窄(PS)2例,室间隔缺损(VSD)并动脉导管未闭(PDA)4例,PDA并PS 2例,ASD并PDA 2例。结果7例1次治疗成功,余3例中2例分2次治疗,1例8个月患儿,因其在最初0.5年随访中发现VSD明显缩小,故先封堵了PDA,目前正在随访中。成功率100%,无严重并发症。经1个月-3年随访,患儿心脏缩小,心脏功能改善。结论在病例选择恰当情况下,对小儿CHD复合畸形进行介入治疗是安全、可行的。     

Transcatheter closure of secundum atrial septal defects, a ventricular septal defect, and a patent arterial duct

We report our clinical experience with the newly developed Amplatzer device in transcatheter closure of nine atrial septal defects (ASDs), one ventricular septal defect (VSD), and one patent arterial duct (PDA). Eleven patients with ASD (age range 2.5-18 years) selected according to the location and size of the defect by transesophageal echocardiography (TEE), a five-year-old patient with muscular VSD and a one-year-old patient with PDA were considered for transcatheter closure with Amplatzer devices. All procedures were performed under general anesthesia with fluoroscopic and TEE guidance, following a routine hemodynamic evaluation in the catheter laboratory. The optimal device size was selected after the balloon sizing of the ASDs. The sizes of the VSD and PDA were measured on TEE and angiography. The patients were discharged at 24 hours, after an evaluation with x-ray, electrocardiogram (ECG), and echocardiography; they were on 3-5 mg/kg/day aspirin and infective endocarditis prophylaxis for six months after the procedure. They were reassessed at six to eight weeks and Holter monitoring was done in addition. Devices were used for nine ASD patients, and for the VSD and the PDA patients. Mean ASD size was 14.3 +/- 5.3 mm at TEE and 18.3 +/- 4.3 mm at balloon sizing (p=0.02). The mean size of the device was 18.7 +/- 4.2 mm. The procedure time and the fluoroscopy time were 46.1 +/- 12.3 and 12.9 +/- 1.6 minutes, respectively. Immediately after the procedure, four patients (44%) had trivial shunts (TS). TS remained in only two during discharge, and no shunt was observed at second evaluation. The devices were similarly applied to VSD (12-7 mm) and PDA (8-6 mm) patients. Both cases had TS immediately, which disappeared at 24 hours. None of the patients had major complications. Junctional rhythm developed in one patient, and another patient had frequent supraventricular extrasystoles. Amplatzer is an effective and safe device for transcatheter closure of ASD, VSD, or PDA, especially in pediatric patients.     

超声心动图在应用Amplatzer封堵器关闭儿童房间隔缺损中的应用价值

目的　评价经胸超声心动图 (TTE)和经食管超声心动图 (TEE)在应用Amplatzer封堵器关闭儿童房间隔缺损(ASD)中的应用价值。方法　对 12例拟诊为继发孔型ASD的儿童 (年龄 2～ 13岁 ) ,应用Amplatzer封堵器经导管关闭ASD。通过TTE和 (或 )TEE在术前显示ASD大小及其边缘的解剖特点 ,术中指导封堵器的放置 ,术后评价疗效。结果　 (1) 12例中 ,TEE排除ASD诊断 1例 ,诊断为下腔型ASD和显示缺损前上缘薄弱者各 1例 ,这 3例未实施封堵术。 (2 )TEE测量ASD大小 (5～ 2 6mm ,平均 13 6mm) ,与ASD伸展径 (7～ 30mm ,平均 16 6mm)具有高度相关性 (r=0 994 ,P <0 0 1) ;与术前TTE测量ASD大小很接近 (5～ 2 1mm ,平均 14 3mm) ,后者与ASD伸展径亦具有高度相关性 (r =0 932 ,P <0 0 1)。 (3) 9例实施封堵术者 ,有 8例封堵成功 ;1例在封堵器释放后 15min发生脱落 ,改为外科修补。 (4) 8例成功实施封堵术者经TTE随访 1～ 2 2个月 ,无残余分流征象。结论　应用Amplatzer封堵器经导管关闭ASD可取得良好效果 ;超声心动图在经导管关闭ASD过程中具有重要价值 ,TTE和TEE各具优点 ,TTE适用于病例的初步筛选和术后随访 ;而TEE则在决定是否进行封堵术和指导封堵器的正确放置等方面发挥重要的作用。     

膜周部室间隔缺损介入治疗并发症的分析

目的　探讨膜周部室间隔缺损 (ventricularseptaldefect ,VSD)经导管介入治疗的并发症及其预防。方法　 2 0 0 2年 7月 - 2 0 0 4年 5月 ,2 6 2 (男 138,女 12 4 )例膜周部VSD患儿 ,年龄 2～ 18(9 3± 5 8)岁 ,体重 11.0～ 6 5 .0 (平均 30 5 )kg。 3例合并动脉导管未闭 ,4例合并房间隔缺损 ,1例合并动脉导管未闭和房间隔缺损。结果　 2 6 2例患儿术前经胸超声检测VSD大小为 2 7～ 13.0mm(平均 6 5mm) ,术中心室造影测量VSD大小为 1 3～ 14 .0mm(平均 6 8mm) ,2 5 6 /2 6 2例 (97 7% )封堵成功。所选封堵器大小为 4～ 16mm (平均 8 6mm)。严重并发症 8例 (3 1% )。其中高度房室传导阻滞(atrioventricularconductionblock ,AVB) 5例 (2 0 % ) ,溶血 2例 (0 8% )。封堵器明显移位 1例 (0 4 % )。5例AVB患儿治疗后除 1例术后 5 0d安装永久起搏器外 ,其余 4例均恢复正常窦性心律。溶血患儿经常规治疗后恢复正常。封堵器明显移位则采用心脏外科手术处理。其他并发症有 :1例 (0 4 % )术后 6个月复查有微量残余分流 ;5例 (2 0 % )术后新出现主动脉瓣微量返流 ;4例 (1 6 % )术后新出现三尖瓣少量返流 ;75例 (2 9% )术后出现间歇性加速性交界性心律或加速性室性自主心律伴干扰性房室脱节 ,治疗后均恢复     

165例5岁以下小儿房间隔缺损的介入治疗

目的总结双盘封堵器(Amplatzer)关闭年龄小、体重轻患儿的继发孔型房间隔缺损(ASD)的病例。方法1998年8月至2004年5月,165例5岁和18kg以下小年龄组继发孔型ASD病例接受Amplatzer封堵器介入治疗。所有患儿均经临床体检、X线胸片、心电图、经胸超声心动图(TTE)确诊为继发孔型ASD。TTE观察和测量ASD和房间隔(IAS)最大径,测量球囊导管测量ASD最大伸展径,必要时加用食道超声(TEE)测定,筛选后的患儿依此选择封堵器。结果163例成功封堵ASD,成功率98.8%。本组ASD最大径(8～30)mm,平均(18.3±5.1)mm,选择封堵器直径(8～30)mm,平均(18.6±5.0)mm,P>0.05。Qp/Qs=3.3±2.0。147例(89.0%)为单纯单孔ASD病例;6例为多孔ASD,其中3例伴有房间隔瘤样改变,均用一个封堵器成功封堵ASD。另外12例合并其他心内畸形,其中6例合并肺动脉瓣狭窄(PS),6例合并动脉导管未闭(PDA)。右心容量超负荷术后明显改善。本组中大ASD占60.0%(100)例。操作上有一定难度。结论Amplatzer封堵器关闭5岁以下儿童房间隔缺损是可行的,但不主张2岁以下行介入治疗。严格掌握适应证;良好的小儿心血管内外科条件是成功封堵的基本保证。     

Interventional pediatric cardiology: Device closures

Surgical treatment of various septal defects has been long established. With the advances in transcatheter therapy dilatation techniques for valvular stenosis and vascular obstruction have become established procedures. Closure of septal defects in the catheterization laboratory has also been introduced; some of these have come into regular use in current practice. In 1967, Porstmannet al reported the use of lvalon plug to close patent ductus arteriosus (PDA). Since then, several devices have been used including Rashkind PDA ocluder (not being used now), Gianturco coils, detachable coils (for small PDA), CardioSEAL and other umbrella devices and Amplatzer PDA occluder. Closure rates vary from 95–98% in most series, however, some of these devices are very expensive, more so, when compared to the cost of surgical ligation of PDA. Catheter closure of secundum atrial septal defect (ASD) has also been done by various devices like clamshell device, Sideris Buttoned device, ASDOS device, amplatzer device and cardioSEAL. So far no device has been accepted as ideal for every case, however, Amplatzer device has been used most extensively. Issues such as completeness of endothelialisation, incidence of late arrhythmias, endocarditis remain uncertain. However, in select population of ASD cases with a central secundum defect, device closure is being used increasingly. Device closure of ventricular septal defect remains challenging and controversial and is probably available to a small group of children with defects that are difficult to close surgically and involve higher risk.     

Comparison of Atrial Septal Defect Closure Using Amplatzer Septal Occluder with Surgery

Our study reports the results of a comparison of closure of atrial septal defect (ASD) surgically with transcatheter closure using the Amplatzer septal occluder. Patients having an ASD and a surgical closure or transcatheter closure between January 1999 and July 2000 were selected. There were 103 patients who had ASD. All 64 patients in group 1 (surgery) had a successful operation, with only 2 patients with a mild residual shunt. There were 39 patients enrolled for transcatheter closure of the ASD (group 2). Four patients were excluded initially. The median age for group 1 was 25 years (range 2.3-64 years) compared to 11.7 years (range 2-69 years) in group 2 (p = 0.035). In group 1, the mean ASD diameter measured was 28.4 +/- 10.2 mm compared to 23.4 +/- 5.7 mm in group 2 (p = 0.003). In 29 patients, devices were deployed with sizes from 10 mm to 30 mm (median 24 mm). Three patients were excluded because a larger device (>30 mm) was not available and devices were not successfully deployed in another 3 patients. One patient had a device embolized into the right ventricle (surgical removal and closure of the ASD). Complications occurred in 13 patients in group 1 and 4 patients in group 2. Complete occlusion occurred in 27 of 28 group 2 patients (96.4%) during the follow-up period (10.2 +/- 5.4 months). The Amplatzer septal occluder is a new device for closure of different-sized ASDs. The intermediate-term follow-up demonstrated excellent closure results. The benefit for each patient was demonstrated in less morbidity and less time spent in the hospital.     

儿童继发孔型房间隔缺损的介入治疗

目的　探讨儿童继发孔型房间隔缺损 (atrialseptaldefect ,ASD)封堵术的指征、方法学和并发症的预防。方法　 1998年 10月～ 2 0 0 3年 1月 ,119例继发孔型ASD患儿 ,根据家属意愿接受了经导管应用Amplatzer房间隔封堵器的介入治疗。年龄 0 8～ 17 0岁 ,平均 ( 7 5± 2 8)岁 ,体重6 7～ 88.0kg ,平均 ( 2 3 7± 7 8)kg。所有病例术前检查被证实均为继发孔型ASD。按ASD球囊伸展直径或大于 1～ 2mm选择封堵器进行堵塞。其中 3例为多发ASD。 6例合并动脉导管未闭 ( patentductusarteriosus,PDA)或肺动脉瓣狭窄 ( pulmonarystenosis ,PS)者应用其他封堵装置和球囊扩张治疗合并的畸形。术后定期行心脏超声及临床检查随访。结果　 119例患儿术前经食道超声(transesophagealechocardiography ,TEE)或经胸超声 (trans thoracicechocardiography ,TTE)检测ASD平均直径 ( 12 9± 5 6 )mm ( 6 5～ 34 5mm ) ,肺动脉平均压力为 ( 2 9 0± 5 0 )mmHg( 2 5 0～ 6 2 0mmHg) ,球囊伸展直径为 ( 15 7± 4 8)mm( 8 0～ 38 0mm)。所选封堵器直径平均为 ( 15 0± 5 0 )mm( 8 0～ 38 0mm)。 112例封堵成功。 3例多发ASD也选用单一封堵器。 6例合并PDA或PS者同时完成介入治疗。 112例堵塞后即刻封堵率为 93 8% ( 1     

经导管同期介入治疗儿童复合型先天性心脏病8例分析及随访

目的：儿童先天性心脏病(congenital heart disease,CHD)复合畸形(复合型CHD)既往外科手术是唯一的治疗方法,随着介入治疗技术的日渐成熟和新型封堵器械的不断出现,经导管同期介入治疗儿童复合型CHD引起人们的关注,目前,国内外报道尚不多。该研究对儿童复合型CHD经导管介入治疗的方法及疗效进行探讨。方法：应用经导管介入治疗方法同期封堵治疗8例儿童复合型CHD,其中男4例、女4例,平均年龄(6.1±2.9)岁,其中房间隔缺损(ASD)伴室间隔缺损(VSD)、动脉导管未闭(PDA)1例,ASD伴PDA、肺动脉瓣狭窄(PS)1例,ASD伴PDA 1例,卵原孔未闭(PFO)伴PS 1例,ASD伴PS 4例。经导管介入治疗的原则是:ASD伴VSD、PDA者,先行VSD封堵术,再行PDA封堵术,最后行ASD封堵术;ASD伴PDA、PS者,先行经皮球囊肺动脉瓣成形术(PBPV)纠正PS,再行PDA封堵术,最后行ASD封堵术;PFO伴PS和ASD伴PS者,先行PBPV纠正PS,其次行PFO或ASD封堵术。结果：8例复合型CHD均1次治疗成功,术中未发生任何严重并发症。术后即刻超声和造影检测显示VSD、ASD及PDA均无残余分流,6例合并PS者,跨肺动脉瓣压差由术前的75.3±15.6 mmHg下降至术后的14.0±5.6 mmHg,经3.4±1.2年随访证实无残余分流,跨瓣压差均在通常标准良好的范围内,无任何并发症发生。结论：经导管介入治疗儿童复合型CHD技术要求较单纯型CHD相对高,宜遵循先难后易、后期操作不影响前面治疗的原则,规范操作,可获良好的治疗效果。     

Transcatheter Closure of a Large Patent Ductus Arteriosus in a Young Child Using the Amplatzer Duct Occluder

The Amplatzer duct occluder (ADO) provides a safe and effective therapy for patients with moderate- to large-sized patent ductus arteriosus (PDA), but there have been few reports of transcatheter closure of very large PDAs in young children and infants. We report a successful transcatheter closure of a very large PDA, 10.5 mm in diameter at the narrowest point, with a 14/12-mm ADO. To our knowledge, this is the largest PDA ever closed by an interventional method in such a young child.     

Progression to Late Complete Atrioventricular Block Following Amplatzer Device Closure of Atrial Septal Defect in a Child

Atrial septal defect (ASD) closure by interventional catheterization techniques has been widely accepted and is considered a standard treatment for this congenital heart defect. We report the case of a 6-year-old girl who presented with progression of first-degree atrio-ventricular (AV) block to symptomatic, complete heart block after ASD closure with an Amplatzer septal occluder (ASO). Although she received steroids immediately after the procedure when second-degree AV block was seen, her AV conduction slowly deteriorated over 4 years, requiring permanent pacemaker implantation. We can only speculate that the injury to the conduction system was the result of persistent trauma, ischemia, or progressive scarring caused by the ASO on the AV nodal region. It is uncertain if early device removal would have prevented this complication. This case highlights the importance of cardiac rhythm monitoring following ASO implantation for ASD closure on long-term follow-up.     

��ɫ�����ճ����Ķ�ͼ�ڷ����ȱ����Ҽ��ȱ����������е�Ӧ��

目的探讨经胸超声心动图(TTE)及实时三维超声心动图在房间隔缺损(ASD)、室间隔缺损(VSD)封堵术中的临床应用价值。方法应用二维及三维超声心动图对2004-10—2005-10在天津市儿童医院就诊的24例继发孔ASD,10例VSD进行术前检查筛选,术中超声引导及术后随访检查。结果24例ASD患儿术前经TTE检测ASD直径(15·6±7·9)mm(5~26mm),所选Mmplatzer封堵器直径为(19·1±5·1)mm(5~32mm),23例封堵成功。室间隔膜部缺损直径:左室面缺损为5~9mm,右室侧口的直径为2·4~6·0mm,术中选择Amplatzer封堵器型号为4~6mm,10例VSD无残余分流。结论二维及三维TTE联合应用于ASD、VSD介入治疗具有很好的应用价值。     

复杂性先天性心脏病的介入治疗

目的探讨先天性心脏病(简称先心病)介入治疗在复杂性先心病中的应用.方法应用Rashkind球囊导管对59例复杂性先心病患儿行球囊房隔造口术(BAS);对2例右室发育不良综合征患儿进行静态球囊房隔扩张造口术;对1例在大动脉转位术后出现肺动脉吻合口狭窄的完全性大动脉转位(TGA)的患儿,采用球囊扩张导管进行扩张;对15例法洛四联症(TOF)患儿进行经皮球囊肺动脉瓣成形术(PBPV)、球囊血管成形术;对18例合并主动脉至肺动脉侧支血管的患儿以及5例B-T分流术的患儿在外科根治术前采用弹簧圈进行侧支血管和分流管道的堵塞术;对1例Fontan手术后的先心病患儿采用Amplatzer房间隔缺损(简称房缺)堵塞装置进行窗孔堵塞术.结果46例TGA患儿BAS后动脉血氧饱和度(SaO2)由0.57±0.17上升至0.76±0.13(t=14.58, P<0.01),左右心房压差﹤2 mmHg(1 mmHg=0.133 kPa),术后房缺5～20 mm;10例肺动脉闭锁伴室间隔完整的患儿BAS后SaO2变化不大(t=1.57, P﹥0.05),左右心房压差﹤2 mmHg;TOF患儿经PBPV及球囊血管成形术后SaO2平均上升15%,肺动脉瓣狭窄解除;18例主动脉至肺动脉侧支血管堵塞术,14例效果良好被完全堵塞;5例B-T分流管道堵塞术,全部封堵成功;1例Fontan手术后窗孔堵塞术,获完全封堵.结论复杂性先心病应用介入治疗和外科手术相配合,可获得更好的疗效.     

Community Use of the Amplatzer Atrial Septal Defect Occluder: Results of the Multicenter MAGIC Atrial Septal Defect Study

The objective of this study was to determine the initial safety and results of unrestricted multi-institution routine community use of the Amplatzer Septal Occluder (ASO) for atrial septal defect (ASD) closure. A multicenter, nonrandomized prospective study was performed in 13 pediatric cardiology centers from November 2004 to September 2007. Data were collected at the time of cardiac catheterization and 1 day postimplant. Four hundred seventy-eight patients underwent cardiac catheterization for ASO device closure of an ASD. The median age was 6 years (range, <1–83 years), and the mean weight was 37.2 kg (range, 2.6–148 kg). Procedural success was 96% (458/478 patients), with deficient rims being the major single reason for failed implantation (9/20). Major and minor complication rates were 1.1% and 4.8%, respectively, and were not different between simple and complex ASD groups. Success at 24 h was 99.4% (333/335) in the simple ASD group and 100% (120/120) in the complex ASD group. The presence of large defects, the presence of multiple defects, the use of multiple devices, and a weight <8 kg were significantly associated with a residual shunt (small to moderate) at 24 h. In conclusion, the ASO device in routine clinical practice for simple and complex ASD closure has an immediate safety and effectiveness profile equal to that reported in the initial pivotal FDA trial for simple ASDs. Based on the evolution in care posed by the ASO and the lack of consensus on patient selection in complex ASDs, this study points out the need to redefine the optimal patient and possibly broaden the indications for device closure of ASDs.     

Quantitative evaluation of the changes in plasma concentrations of cardiac natriuretic peptide before and after transcatheter closure of atrial septal defect

The purpose of this study was to investigate the changes in plasma concentrations of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in patients with atrial septal defect (ASD) during transcatheter closure of defects. The plasma concentrations of ANP and BNP were obtained from 14 patients with ASD at before closure, and at 5 min, 24 h, 1 mo and 3 mo after transcatheter ASD closure using an Amplatzer septal occluder. Ten healthy children aged 6-18 y were studied as controls. All ASDs were successfully closed. Compared with control values (mean +/- SD, 17 +/- 6.8 ng 1(-1), ANP concentrations before closure were significantly elevated (24 +/- 9.8ng 1(-1), p < 0.05). ANP concentrations increased significantly at 5 min after closure (34 +/- 18 ng 1(-1), p < 0.05) compared with preclosure concentrations. At 24 h after closure, the concentrations decreased to values not different from control values (19 +/- 11 ng 1(-1), p = ns). BNP levels before closure (19 +/- 9.9 ng 1(-1) were also elevated significantly compared with control values (12 +/- 4.9ng 1(-1), p < 0.05). BNP concentrations increased significantly at 5 min after closure (23 +/- 14 ng 1(-1), p < 0.05) compared with preclosure concentrations. ANP values at 24 h were lower than at 5 min after closure, whereas BNP values were higher (32 +/- 11 ng 1(-1), p < 0.05). As with ANP, the concentrations gradually decreased to values not different from control values at 3 mo after the procedure (12 +/- 6.3 ng 1(-1), p = ns). CONCLUSION: Plasma concentrations of ANP and BNP may become effective markers for evaluating changes in cardiac load after transcatheter ASD closure.     

Helex Septal Occluder: Feasibility Study of Closure of Atrial Septal Defect

Background A variety of transcatheter atrial septal defect (ASD) occluders are currently in use, the most commonly used device is the Amplatzer Septal Occluder (ASO) yet there is no perfect device. The Helex Septal Occluder is a new device (by W.L. Gore & Associates, Inc.) designed to improve the results of transcatheter ASD closure. We report our first experience in closing secundum ASDs with this new device after its recent modifications. Methods Thirteen patients were selected for Helex device closure with median age of 8 years (2.5–44 years) and median weight 30 Kg (12–96 Kg). Inclusion criteria were: small to moderate Secundum ASDs with sufficient rims by transthoracic echo (TTE) and confirmed by transoesophageal echo (TEE). Two cardiologists carried out the decision of device size. One of the five available Helex ASD device sizes was used (15–35 mm). Follow up TTE was performed the next day, one month, six months and one year later. Results Twelve patients had successful Helex septal occluder implantation. One patient was switched to Cribriform ASD device during the procedure because of failure of the locking mechanism. Two patients had trivial residual left to right shunt which disappeared at one month follow up in one patient. No embolic event, AV block or mortality was observed. Conclusion This feasibility study of the novel Helex septal occluder after its recent modification showed that it can successfully and safely close well selected secundum ASDs. There are several advantages over the currently available devices.     

小儿先天性心脏病介入治疗后心肌损伤和炎症反应的研究

目的：研究先天性心脏病（CHD）介入治疗后7 d心肌损伤和炎症反应。方法：选择77例CHD患儿,其中室间隔缺损（VSD）12例,肺动脉瓣狭窄(PS)14例,房间隔缺损（ASD）14例,动脉导管未闭（PDA）37例。检测术后即刻、术毕、术后6 h、24 h、72 h及7 d 的血清心肌酶（AST、CK、CKMB）、肌钙蛋白I(cTnI)和CRP值的变化。结果：VSD组AST水平于术后即刻,术后6 h和术后24 h明显高于其他3种类型CHD组（P<0.05）;术后即刻及术后6 h各组间CK及CKMB水平差异有统计学意义,以VSD组最高;术后72 h和术后7 d PDA组CRP水平明显高于其他3种类型CHD组（P<0.05）。与术前相比,术后6 h和24 h,4种类型CHD组AST均明显升高（P<0.05）;术后即刻和术后6 h,VSD组CK和CKMB水平较术前明显升高（P<0.05）;术后即刻和术后6 h,VSD、PDA和PS组cTnI水平较术前明显升高（P<0.05）;PDA组CRP水平术后24 h、72 h和7 d较术前明显升高（P<0.05）。结论：介入治疗CHD 7 d内可引起轻微心肌损伤,以VSD明显,主要集中在术毕至术后24 h较短时间内,未引起明显炎症反应。     

膜周部室间隔缺损经导管封堵术后早期心律失常危险因素的探讨

目的心律失常是经导管封堵膜周部室间隔缺损术后的常见并发症,不仅影响术后心功能的恢复,而且直接关系到预后。分析18岁以内患者膜周部室间隔缺损经导管封堵术后早期心律失常及其危险因素,以期降低术后心律失常的发生率。方法2002年6月—2004年6月,89例膜周部室间隔缺损患者根据家长意愿接受了经导管应用Amplatzer装置及国产封堵器进行堵塞。80例应用AGA公司制造的Amlatzer膜周部室间隔缺损封堵器,9例应用国产封堵装置,术后定期行心脏超声及心电图检查。结果89例膜周部室间隔缺损封堵术均获成功。11例术后5d内发生了不同类型的传导阻滞,发生率为12%,分别为Ⅰ°房室传导阻滞1例,Ⅲ°房室传导阻滞1例,左前分支阻滞5例,不完全(部分)性右束支传导阻滞4例,完全性右束支传导阻滞3例,其中3例并发两种传导阻滞。分析本组心律失常的影响因素,发现:(1)室间隔缺损上缘距主动脉右冠瓣距离<3mm;(2)室间隔缺损直径≥8mm,封堵器直径≥10mm;(3)穿刺成功后动脉静脉(A-V)轨道建立时间≥60min及术中pH值<7·35与心律失常密切相关。结论心律失常是膜周部室间隔缺损封堵术后早期严重的并发症;严格选择手术适应证、缩短手术操作时间、防止酸中毒是降低膜周部室间隔缺损介入封堵术后心律失常发生率的有效措施。     

Transcatheter Closure of Multiple Perimembranous Ventricular Septal Defects With Septal Aneurysm Using Two Overlapping Amplatzer Duct Occluders II

Ventricular septal defect (VSD) is a common congenital heart defect in children. Perimembranous VSD (Pm VSD), a defect involving the membranous septum and the adjacent portion of the muscular septum, accounts for about 70 % of cases. Transcatheter closure of Pm VSDs using the Amplatzer Pm VSD device, although successful in many patients, has been associated with major adverse events. Complete heart block, thromboembolism, and new-onset valvular regurgitations in patients undergoing VSD closure using the Pm VSD occluder have been reported [3]. Recently, a new retrograde approach for transcatheter closure of Pm VSDs using the Amplatzer Duct Occluder II (ADO II) has been described with a 90 % success rate [1]. This report describes a child who had multiple Pm VSDs with septal aneurysm undergoing successful transcatheter closure using two ADO II occluders with relative ease.     

Percutaneous closure of a mid-muscular residual ventricular septal defect using the Amplatzer(TM) device

We present the case of a 6-year old boy with a mid-muscular residual ventricular septal defect (VSD) of difficult surgical access, who underwent transcatheter closure using the Amplatzer(TM) VSD occluder. Transcatheter closure was guided by transthoracic echocardiography and successful closure was achieved with a 12 mm diameter VSD occluder, with no complications. Chest radiography showed a considerable decrease in cardiomegaly and normalization of pulmonary vascular markings before 24 hours, and echocardiography showed correct positioning of the Amplatzer(TM) VSD device without residual shunt through the device and minimal residual shunt in an apical VSD. After a 3-month follow-up, the patient was asymptomatic and echocardiography showed that the device was correctly positioned with minimal residual apical shunt.